Optimization and Scale-Up of RNA Therapeutics Through Next-Generation Manufacturing
RNA-based therapies and vaccines represent a versatile and preferred approach to addressing several major public health challenges. However, their production requires RNA to be encapsulated, stabilized, and delivered to the body using nanosuspensions complex structures that must be custom-formulated depending on the targeted organ or cells. This level of customization presents a significant challenge for large-scale production.
This project is a collaboration between Professor Xavier Banquy and Davide Brambilla from Université de Montréal and Daria Boffito and Bruno Blais from Polytechnique Montréal. The team is receiving $1,240,360 in funding through Médicament Québec, with financial support from the Government of Québec, to develop an innovative new manufacturing platform for nanosuspensions based on the use of rotating disc mixers (SDM). Optimized by artificial intelligence, this technology will allow for precise control of production parameters and facilitate industrial-scale manufacturing, while complying with strict pharmaceutical standards.
This project goes far beyond technical optimization: it proposes a new standard to make vaccines and biotherapies more accessible on a global scale. It is a structuring initiative supported by Montréal-based company RNA Technologies & Therapeutics, German company Lipoid GmbH, and Dutch company Flowid B.V. Thanks to their contribution, the total project value amounts to $1,865,860.
This funding will not only strengthen Québec’s strategic position in the field of advanced biopharmaceutical production but also respond to a growing need within the industry both in Québec and internationally.
Comments are closed.